Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Suprax Articles

Mylan debuts generic Antara; FDA approves generics of Actavis' Suboxone, Lupin's Suprax and Zydus' Zantac

25 February 2013

13.7% growth for Indian pharma recorded 13.7%to $9.43 billion in first three quarters of fiscal 2009-10

4 February 2010

India's Lupin in US marketing deal for Suprax

30 June 2008

Nepal researchers say $1 product treats typhoid better than WHO drug

23 July 2007

Cornerstone and Lupin in Suprax deal

7 February 2005

Lupin launches oral generic cefixime in USA

19 April 2004

Lupin and Allergan collaborate on Zymer promo to US pediatricians

5 April 2004

Lupin gets US ANDA for cefixime suspension

15 March 2004

Lupin to launch cefixime in USA

16 June 2003

Fujisawa and Elder sign marketing pact

2 March 2000

Net Loss Plunges To $270 Million At Fujisawa

21 May 1998

New Data With Glaxo Wellcome's Raxar

9 June 1997

Fujisawa Sees 31% Net Income Rise For FY1996

26 May 1997

Japan's Fujisawa Looks To 21 Century Growth

16 October 1995

Fujisawa Net Down Though Operating Income Soars

29 May 1995

US PRODUCT NEWS IN BRIEF

18 April 1994

JAPAN DRUGMAKERS' FOREIGN SALES STILL LOW

26 July 1993

PEDIATRIC CEFZON LAUNCHED IN JAPAN

14 June 1993

FUJISAWA'S PROMISING R&D PIPELINE

9 November 1992

FUJISAWA HIT BY JAPAN DRUG PRICING MOVES

1 June 1992

FUJISAWA TAIWAN PLANT PLANNED

13 April 1992

FUJISAWA TAIWAN PLANT PLANNED

13 April 1992

FUJISAWA KOREA JV COMPLETED

9 March 1992

FUJISAWA'S CEFZON LAUNCHED IN JAPAN

6 January 1992

Showing 1-24 of 24 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS